|Day Low/High||118.10 / 119.79|
|52 Wk Low/High||63.48 / 121.06|
Jim Cramer says Freshpet is only a takeover play and suggests buying Zoetis or Idexx Labs instead.
MGM: 'I like the CEO and I like the REIT,' Jim Cramer says.
Know which stocks are interest-rate sensitive and which don't care, says Jim Cramer.
The animal health industry looks poised for growth, analysts say, and Idexx Laboratories IDXX stands to benefit.
Cramer is sticking with International Paper and likes Advanced Micro Devices.
This is not the time to sell in a panic, Cramer says.
These stocks have both short-term gain catalysts and longer-term growth potential.
TheStreet's Jim Cramer says the humanization of pets is a growing investment opportunity.
The humanization of pets has sent spending soaring, which has some pet-related stock seeing major benefits.
Cramer shares his views on the winners and losers of this earnings season. Comcast, Idexx Laboratories and Zoetis are among the stocks discussed.
Cramer has seen enough in this earnings season to come to some conclusions on what's working and what isn't.
With enough of earnings season now under our belt, we check out the promising themes and the sectors to avoid.
Trade-Ideas LLC identified IDEXX Laboratories (IDXX) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
Trade-Ideas LLC identified IDEXX Laboratories (IDXX) as a new lifetime high candidate
Legiolert™radically simplifies Legionella water testing compared to current culture methods
Trade-Ideas LLC identified IDEXX Laboratories (IDXX) as a strong and under the radar candidate
Cramer is faithful to pet care drug maker Zoetis and he prefers Danaher over its split-off sibling Fortive.
Johnson & Johnson was easy, Cramer says, but other stocks were more problematic.
Sequoia Fund has sold its position in Valeant Pharmaceuticals and has added four new positions.
The company once held a 30% stake in Valeant, now owns no Valeant shares.